Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Sees Large Decrease in Short Interest

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) was the recipient of a large decrease in short interest in January. As of January 15th, there was short interest totalling 4,540,000 shares, a decrease of 17.5% from the December 31st total of 5,500,000 shares. Based on an average trading volume of 1,310,000 shares, the short-interest ratio is currently 3.5 days.

Institutional Trading of Zentalis Pharmaceuticals

A number of hedge funds and other institutional investors have recently made changes to their positions in ZNTL. China Universal Asset Management Co. Ltd. lifted its holdings in Zentalis Pharmaceuticals by 63.9% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 13,676 shares of the company’s stock worth $50,000 after buying an additional 5,333 shares in the last quarter. Carson Advisory Inc. raised its position in shares of Zentalis Pharmaceuticals by 55.8% during the third quarter. Carson Advisory Inc. now owns 24,570 shares of the company’s stock worth $90,000 after acquiring an additional 8,800 shares during the last quarter. Erste Asset Management GmbH acquired a new position in shares of Zentalis Pharmaceuticals during the third quarter valued at $37,000. Paloma Partners Management Co bought a new position in Zentalis Pharmaceuticals in the third quarter valued at about $37,000. Finally, 49 Wealth Management LLC increased its position in Zentalis Pharmaceuticals by 81.7% in the third quarter. 49 Wealth Management LLC now owns 22,558 shares of the company’s stock worth $83,000 after purchasing an additional 10,145 shares during the period.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on ZNTL shares. Guggenheim cut their price target on Zentalis Pharmaceuticals from $12.00 to $8.00 and set a “buy” rating for the company in a research note on Friday, November 15th. Wells Fargo & Company reduced their target price on shares of Zentalis Pharmaceuticals from $8.00 to $6.00 and set an “equal weight” rating for the company in a research note on Thursday. HC Wainwright dropped their price target on shares of Zentalis Pharmaceuticals from $20.00 to $10.00 and set a “buy” rating on the stock in a research note on Wednesday. UBS Group reduced their price objective on shares of Zentalis Pharmaceuticals from $5.00 to $2.20 and set a “neutral” rating for the company in a research note on Tuesday. Finally, Wedbush reiterated a “neutral” rating and issued a $4.00 price objective on shares of Zentalis Pharmaceuticals in a report on Friday, January 24th. Five investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $8.24.

Zentalis Pharmaceuticals Price Performance

Zentalis Pharmaceuticals stock opened at $1.74 on Friday. Zentalis Pharmaceuticals has a 52-week low of $1.66 and a 52-week high of $18.07. The stock has a fifty day moving average price of $2.94 and a two-hundred day moving average price of $3.27. The firm has a market capitalization of $124.00 million, a P/E ratio of -0.70 and a beta of 1.86.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last announced its earnings results on Tuesday, November 12th. The company reported ($0.56) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.92) by $0.36. On average, equities research analysts predict that Zentalis Pharmaceuticals will post -2.48 EPS for the current fiscal year.

About Zentalis Pharmaceuticals

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.